Oncotelic’s PDAOAI Platform to Debut at Qdrant Vector Space Day

Oncotelic Therapeutics (OTCQB: OTLC) is set to showcase its proprietary PDAOAI(TM) drug discovery and development platform at the Qdrant Vector Space Day 2026 in San Francisco on June 11. The platform, which operates on Qdrant infrastructure, has accelerated the development of two drug candidates from concept to investigational new drug filings in under two years, dramatically reducing the time and cost typical of pharmaceutical development. Company executives will join Qdrant leadership to discuss the platform's innovations, including a proprietary “manifold folding” technique that enhances semantic retrieval accuracy and reduces large language model hallucinations, as well as the indexing of approximately 28 million PubMed biomedical abstracts on Qdrant Cloud. This integration of advanced vector search technologies supports large-scale biomedical research and accelerates oncology drug discovery.

Oncotelic Therapeutics is a clinical-stage biopharmaceutical company focused on oncology and immunotherapy products, targeting high-unmet-need cancers and rare pediatric indications. The company benefits from a robust portfolio of inventions by its CEO, Dr. Vuong Trieu, who has filed over 500 patent applications and holds 75 issued patents. Beyond its internal pipeline, Oncotelic licenses and co-develops drug candidates through strategic partnerships and joint ventures, including a 45% interest in GMP Bio. The PDAOAI platform is central to the company's research, biomarker discovery, and regulatory processes, leveraging AI to integrate and analyze vast datasets.

The news was distributed by BioMedWire, a specialized communications platform within the Dynamic Brand Portfolio @ IBN, which provides wire solutions, editorial syndication to over 5,000 outlets, and social media distribution. For more details, the full press release is available at https://ibn.fm/Ce72F, and the latest updates on OTLC can be found at https://ibn.fm/OTLC.